MYRBETRIQ® (mirabegron) logo
  • Myrbetriq is the #1 prescribed branded OAB medication1*

    *Based on 24-month TRx shares for all branded OAB medications, IMS Health National Prescription Audit, January 2019–December 2020.

    THIS INFORMATION DOES NOT IMPLY SAFETY OR EFFICACY OF ANY PRODUCT. NO COMPARISON SHOULD BE MADE.

  • Urologists and Ob-Gyns
    choose Myrbetriq more than any other OAB medication1*

    *Based on 12-month TRx shares for all OAB medications, IMS Health National Prescription Audit, January–December 2020.

    THIS INFORMATION DOES NOT IMPLY SAFETY OR EFFICACY OF ANY PRODUCT.
    NO COMPARISON SHOULD BE MADE.

  • Since its launch in 2012, nearly 2.5 million patients have taken Myrbetriq to help manage their OAB symptoms, with more than 17.6 million written1,3*

    *Based on IQVIA and SHA claims data of Myrbetriq total prescription volume and patient counts for weeks ending 10-05-2012 through 07-17-2020. Myrbetriq patient count was projected (Astellas internal methodology) based on SHA patient-to-prescription ratio applied to IQVIA data.

  • According to the AUA/SUFU Guideline, behavioral therapies may be combined with Myrbetriq as a first-line treatment option2*

    *Other pharmacologic treatment options may also be combined with behavioral therapies for first-line use. Adapted from AUA/SUFU (American Urological Association/Society of Urodynamics, Female Pelvic Medicine, & Urogenital Reconstruction) non-neurogenic OAB guidelines.

  • Myrbetriq is the only β3-adrenergic agonist with dosing flexibility and an FDA-approved combination therapy indication—helping you tailor your patient’s needs throughout their treatment journey3

  • Your elderly patients ≥65 years can see meaningful improvement in daily OAB symptoms of urinary incontinence, frequency, and volume voided with Myrbetriq4*

    See data from the PILLAR study >

    *Myrbetriq was evaluated in a pre-specified subgroup analysis of patients ≥65 years of age from three Phase III pivotal clinical trials. Myrbetriq was also studied in the PILLAR trial—a prospective, double-blind, randomized, placebo-controlled, parallel-group, multicenter Phase IV study of community-dwelling patients ≥65 years of age with wet OAB symptoms for ≥3 months.

  • Myrbetriq is covered without restrictions for 99% of insured patients in Medicare Part D plans1*†

    FORMULARY STATUS DOES NOT IMPLY SAFETY OR EFFICACY OF ANY PRODUCT;
    NO COMPARISONS SHOULD BE MADE.
    A product’s placement on a plan’s formulary involves a variety of factors known only to the applicable plan.

    *Formulary data sourced from Managed Markets Insight & Technology as of November 30th, 2020. Provider communication only–not approved for prescription drug plan member distribution. Formulary status is not a guarantee. Please verify co-pay, coverage and updated information with the plan sponsors. Information subject to change without notice. Astellas does not endorse any individual plans.
    †By Medicare covered lives (46,965,639); Plan types: Medicare MA, Medicare PDP, Source: Data on file as of November 2020 (without restrictions = no prior authorization, no step therapy, and no generic first).

  • The Federal Aviation Administration (FAA) accepts Myrbetriq for OAB treatment5

Important Safety Information, Indications and Usage

INDICATIONS AND USAGE

MYRBETRIQ® (mirabegron extended-release tablets), either alone or in combination with the muscarinic antagonist solifenacin succinate, is indicated for the treatment of overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency.

IMPORTANT SAFETY INFORMATION

MYRBETRIQ® (mirabegron extended-release tablets) is contraindicated in patients with known hypersensitivity reactions to mirabegron or any inactive ingredients of the tablet.

MYRBETRIQ monotherapy or in combination with solifenacin succinate can increase blood pressure in adults. Periodic blood pressure determinations are recommended, especially in hypertensive patients. MYRBETRIQ is not recommended for use in patients with severe uncontrolled hypertension (defined as systolic blood pressure ≥ 180mm Hg and/or diastolic blood pressure ≥ 110mm Hg). Worsening of pre-existing hypertension was reported infrequently in patients taking MYRBETRIQ.

In patients taking MYRBETRIQ, urinary retention has been reported in patients with bladder outlet obstruction (BOO) and in patients taking muscarinic antagonist medications for the treatment of OAB. A controlled clinical safety study in patients with BOO did not demonstrate increased urinary retention in patients treated with mirabegron; however, MYRBETRIQ should still be administered with caution to patients with clinically significant BOO. For example, monitor these patients for signs and symptoms of urinary retention. MYRBETRIQ should also be administered with caution to patients taking muscarinic antagonist medications for the treatment of OAB, including solifenacin succinate.

Angioedema of the face, lips, tongue and/or larynx has been reported with MYRBETRIQ. In some cases, angioedema occurred after the first dose. Cases have been reported to occur hours after the first dose or after multiple doses. Angioedema, associated with upper airway swelling, may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, promptly discontinue MYRBETRIQ and initiate appropriate therapy and/or measures necessary to ensure a patent airway.

Since MYRBETRIQ is a moderate CYP2D6 inhibitor, the systemic exposure to CYP2D6 substrates is increased when co‐administered with MYRBETRIQ. Therefore, appropriate monitoring and dose adjustment may be necessary, especially with narrow therapeutic index drugs metabolized by CYP2D6.

In clinical trials, the most commonly reported adverse reactions in adults (> 2% and > placebo) for MYRBETRIQ 25mg and 50mg versus placebo, respectively, were hypertension (11.3%, 7.5% vs. 7.6%), nasopharyngitis (3.5%, 3.9% vs. 2.5%), urinary tract infection (4.2%, 2.9% vs. 1.8%), and headache (2.1%, 3.2% vs. 3.0%).

In clinical trials, the most commonly reported adverse reactions in adults (> 2% and > placebo and > comparator) for MYRBETRIQ in combination with solifenacin succinate 25mg + 5mg and 50mg + 5mg versus MYRBETRIQ 25mg, MYRBETRIQ 50mg, solifenacin succinate 5mg, and placebo, respectively, were dry mouth (9.3%, 7.2% vs. 3.8%, 3.6%, 6.5%, 2.2%), urinary tract infection (7.0%, 4.0% vs. 4.0%, 4.2%, 3.6%, 5.3%), constipation (4.2%, 3.9% vs. 1.2%, 2.8%, 2.4%, 1.2%), and tachycardia (2.2%, 0.9% vs. 1.6%, 1.6%, 0.7%, 0.8%).

In postmarketing experience with mirabegron, the following events have also occurred: atrial fibrillation, nausea, diarrhea, and dizziness.

Please refer to prescribing information for solifenacin succinate when prescribing MYRBETRIQ in combination with solifenacin succinate.

Please click here for full Prescribing Information for Myrbetriq® (mirabegron extended-release tablets)

References

  1. Astellas. Myrbetriq. Data on File.
  2. Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. American Urological Association Education and Research, Inc. 2019.
  3. Myrbetriq [package insert]. Northbrook, IL: Astellas Pharma US, Inc.
  4. Wagg A, Staskin D, Engel E, Herschorn S, Kristy RM, Schermer CR. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur Urol 2020;77(2):211-20.
  5. Federal Aviation Administration. Federal Air Surgeon’s Medical Bulletin. Oklahoma City, OK: Federal Aviation Administration. 2013‑2014;51(4):1-14.